American Banking and Market News logo

The Latest Headlines at American Banking and Market News

Image about Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (NASDAQ:CRESY) Shares Pass Above 200 Day Moving Average of $8.51

Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (NASDAQ:CRESY) Shares Pass Above 200 Day Moving Average of $8.51

Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (NASDAQ:CRESY – Get Free Report)’s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving... More of this article »
Image about Good Times Restaurants (NASDAQ:GTIM) Stock Price Crosses Above Two Hundred Day Moving Average of $2.55

Good Times Restaurants (NASDAQ:GTIM) Stock Price Crosses Above Two Hundred Day Moving Average of $2.55

Shares of Good Times Restaurants Inc. (NASDAQ:GTIM – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.55 and traded as high as $2.60. Good Times... More of this article »
Image about China Green Agriculture (NYSE:CGA) Shares Cross Above Two Hundred Day Moving Average of $2.45

China Green Agriculture (NYSE:CGA) Shares Cross Above Two Hundred Day Moving Average of $2.45

China Green Agriculture, Inc. (NYSE:CGA – Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.45 and traded as high as $2.85. China Green Agriculture... More of this article »
Image about Rollins (NYSE:ROL) Given “Neutral” Rating at UBS Group

Rollins (NYSE:ROL) Given “Neutral” Rating at UBS Group

UBS Group reaffirmed their neutral rating on shares of Rollins (NYSE:ROL – Free Report) in a research note released on Monday morning, Marketbeat Ratings reports. The brokerage currently has a $49.00 price objective on the business... More of this article »
Image about Veru (NASDAQ:VERU) Given “Outperform” Rating at Oppenheimer

Veru (NASDAQ:VERU) Given “Outperform” Rating at Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of Veru (NASDAQ:VERU – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $5.00 price target on the stock,... More of this article »
Image about ASLAN Pharmaceuticals’ (ASLN) Buy Rating Reaffirmed at HC Wainwright

ASLAN Pharmaceuticals’ (ASLN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN – Free Report) in a research report released on Monday morning, Benzinga reports. HC Wainwright currently has a $9.00 price objective... More of this article »
Image about adidas (OTCMKTS:ADDYY) Upgraded to “Overweight” by Morgan Stanley

adidas (OTCMKTS:ADDYY) Upgraded to “Overweight” by Morgan Stanley

Morgan Stanley upgraded shares of adidas (OTCMKTS:ADDYY – Free Report) from an underweight rating to an overweight rating in a research report sent to investors on Monday morning, Marketbeat reports. Separately, Royal Bank of... More of this article »
Image about NIO (NYSE:NIO) Receives New Coverage from Analysts at Macquarie

NIO (NYSE:NIO) Receives New Coverage from Analysts at Macquarie

Macquarie began coverage on shares of NIO (NYSE:NIO – Free Report) in a research note issued to investors on Monday, Marketbeat Ratings reports. The firm issued a neutral rating and a $5.00 price target on the stock. Other equities... More of this article »
Image about XPeng (NYSE:XPEV) Now Covered by Analysts at Macquarie

XPeng (NYSE:XPEV) Now Covered by Analysts at Macquarie

Macquarie initiated coverage on shares of XPeng (NYSE:XPEV – Free Report) in a research report sent to investors on Monday morning, MarketBeat.com reports. The brokerage issued a neutral rating and a $7.00 target price on the... More of this article »
Image about Astera Labs (NASDAQ:ALAB) Receives New Coverage from Analysts at Roth Mkm

Astera Labs (NASDAQ:ALAB) Receives New Coverage from Analysts at Roth Mkm

Roth Mkm assumed coverage on shares of Astera Labs (NASDAQ:ALAB – Free Report) in a report released on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $85.00 target price on the stock. Separately,... More of this article »
Image about Wells Fargo & Company (NYSE:WFC) Receives “Market Perform” Rating from Oppenheimer

Wells Fargo & Company (NYSE:WFC) Receives “Market Perform” Rating from Oppenheimer

Oppenheimer reiterated their market perform rating on shares of Wells Fargo & Company (NYSE:WFC) in a report released on Monday morning, Benzinga reports. A number of other equities research analysts have also recently issued... More of this article »
Image about Astera Labs (NASDAQ:ALAB) Now Covered by Analysts at Needham & Company LLC

Astera Labs (NASDAQ:ALAB) Now Covered by Analysts at Needham & Company LLC

Needham & Company LLC started coverage on shares of Astera Labs (NASDAQ:ALAB – Free Report) in a report issued on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $85.00 target price on the... More of this article »
Image about Astera Labs (NASDAQ:ALAB) Coverage Initiated by Analysts at Stifel Nicolaus

Astera Labs (NASDAQ:ALAB) Coverage Initiated by Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of Astera Labs (NASDAQ:ALAB – Free Report) in a research note issued to investors on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $81.00 target price... More of this article »
Image about AMCON Distributing (NYSEAMERICAN:DIT) Now Covered by Analysts at StockNews.com

AMCON Distributing (NYSEAMERICAN:DIT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of AMCON Distributing (NYSEAMERICAN:DIT – Free Report) in a report published on Monday morning. The brokerage issued a hold rating on the stock. Separately, TheStreet downgraded shares of... More of this article »
Image about LENZ Therapeutics (NASDAQ:LENZ) Receives New Coverage from Analysts at William Blair

LENZ Therapeutics (NASDAQ:LENZ) Receives New Coverage from Analysts at William Blair

William Blair initiated coverage on shares of LENZ Therapeutics (NASDAQ:LENZ – Free Report) in a research report sent to investors on Monday morning, MarketBeat.com reports. The brokerage issued an outperform rating on the stock. LENZ... More of this article »